Regenxbio (RGNX) EBIT Growth (3y) (2017 - 2026)
Powered by 
Analysis
Regenxbio (RGNX) EBIT Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -18.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.27% |
| 10 | Regenxbio | 472.74 Mn | 367.22 Mn | - | 33.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.89% |
| Dec 31, 2025 | 0.08% |
| Sep 30, 2025 | 9.64% |
| Jun 30, 2025 | -0.40% |
| Mar 31, 2025 | 29.46% |
| Dec 31, 2024 | -29.34% |
| Sep 30, 2024 | -2.68% |
| Jun 30, 2024 | -2.38% |
| Mar 31, 2024 | -13.19% |
| Dec 31, 2023 | -6.00% |
| Sep 30, 2023 | -88.11% |
| Jun 30, 2023 | -20.45% |
| Mar 31, 2023 | -20.62% |
| Dec 31, 2022 | -12.73% |
| Sep 30, 2022 | -25.55% |
| Jun 30, 2022 | -19.25% |
| Mar 31, 2022 | -25.83% |
| Dec 31, 2021 | 403.97% |
| Sep 30, 2021 | -36.15% |
| Jun 30, 2021 | -117.04% |